Volibris is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity (see Pharmacology: Pharmacodynamics under Actions). Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign Out
